{"id":18608,"date":"2014-04-03T12:04:40","date_gmt":"2014-04-03T16:04:40","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=18608"},"modified":"2014-04-03T12:04:40","modified_gmt":"2014-04-03T16:04:40","slug":"cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608","title":{"rendered":"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0<b>CytRx Corporation (NASDAQ:CYTR),<\/b> a biopharmaceutical research and development company focusing on oncology, announced that it will present the results obtained from an in-vivo study of aldoxorubicin\u00a0at the American Association for Cancer Research Annual Meeting.<\/p>\n<p style=\"text-align: justify;\"><b>Positive Phase 2 Results<\/b><\/p>\n<p style=\"text-align: justify;\">CytRx Corporation (NASDAQ:CYTR) seeks to present the detailed results of the positive outcome from the study which was conducted in an animal representation of glioblastoma at the AACRAM which will be held from between April 5 and April 9 in San Diego, CA. The data from the trail demonstrate that aldoxorubicin increased survival by more than twice as compared to doxorubicin treatment. The trail deployed a model of in vivo xenograft tumor featuring glioblastoma multiforme (GBM) tumors in the brains of mouse. Aldoxorubicin showed preferential accumulation as well as prolonged retention in the tumor tissue, which is not observed with doxorubicin. Along with the safety profile of aldoxorubicin, these data give way to its development as a treatment for GBM tumors in patients.<\/p>\n<p style=\"text-align: justify;\"><b>Superiority Over Doxorubicin<\/b><\/p>\n<p style=\"text-align: justify;\">CytRx Corporation (NASDAQ:CYTR) is conducting a Phase 2 trial to analyze the effectiveness of aldoxorubicin in patients in the later stages of GBM. Towards the end of the previous year, the company had reported obtaining impressive results in its global Phase 2 clinical trial which was based on analyzing aldoxorubicin as a first line treatment in those who had soft tissue sarcomas. Aldoxorubicin was seen to demonstrate from 80% to 100% superiority\u00a0in progression-free survival after the trail when the results were compared with doxorubicin. Statistical results marking median and 6 month PFS showed high preference of aldoxorubicin therapy over doxorubicin.<\/p>\n<p style=\"text-align: justify;\">The company is also studying aldoxorubicin in a Phase 2 trial in the treatment of HIV related Kaposi\u2019s sarcoma. Apart from this, as part of a special protocol analysis, CytRx Corporation (NASDAQ:CYTR) has also started a pivotal Phase 3 trial with aldoxorubicin\u00a0 as a treatment for patients having soft tissue sarcomas.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company focusing on oncology, announced that it will present the results obtained from [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":18615,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3158,3159],"stock_ticker":[],"class_list":["post-18608","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cytrx-corporation-nasdaqcytr","tag-nasdaqcytr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company focusing on oncology, announced that it will present the results obtained from [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-03T16:04:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"522\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting\",\"datePublished\":\"2014-04-03T16:04:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg\",\"keywords\":[\"CytRx Corporation (NASDAQ:CYTR)\",\"NASDAQ:CYTR\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\",\"name\":\"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg\",\"datePublished\":\"2014-04-03T16:04:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg\",\"width\":1024,\"height\":522},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608","og_locale":"en_US","og_type":"article","og_title":"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting - Wall Street PR","og_description":"Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company focusing on oncology, announced that it will present the results obtained from [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-04-03T16:04:40+00:00","og_image":[{"width":1024,"height":522,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting","datePublished":"2014-04-03T16:04:40+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg","keywords":["CytRx Corporation (NASDAQ:CYTR)","NASDAQ:CYTR"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608","name":"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg","datePublished":"2014-04-03T16:04:40+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/cytrx-corporation.jpg","width":1024,"height":522},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cytrx-corporation-nasdaqcytr-to-present-results-of-in-vivo-study-of-aldoxorubicin-at-the-american-association-for-cancer-research-annual-meeting-18608#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"CytRx Corporation (NASDAQ:CYTR) To Present Results Of In-Vivo Study Of Aldoxorubicin At The American Association For Cancer Research Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/18608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=18608"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/18608\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/18615"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=18608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=18608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=18608"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=18608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}